---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-032502"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2026-10-13T12:36:31+00:00"
generated_at: "2026-10-13T12:40:14.834360+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CervoMed reports Phase 2a nfvPPA data: plasma NfL fell ~3.1 pg/mL over 12 weeks; 24-week data Nov 2026

## Summary
- Open-label Phase 2a in nfvPPA (NCT07033481): 25 participants; neflamapimod 40 mg TID (n=19) or 80 mg BID (n=6) for 24 weeks, then 12-week randomized withdrawal.
- Baseline: 18/25 (72%) had elevated NfL; mean NfL 45.7 pg/mL (SD 39.6); 4/25 (16%) elevated GFAP, mean 103.4 pg/mL (SD 43.2).
- Mean plasma NfL fell ~3.1 pg/mL over 12 weeks; in 13 participants with baseline NfL at/above median, mean reduction was ~5.7 pg/mL. GFAP stable.
- Neflamapimod generally well tolerated; one patient with elevated liver enzymes met discontinuation criteria, asymptomatic, resolved after stopping; no new safety signals.
- 24-week biomarker data to be presented at CTAD in November 2026; topline clinical data expected Q1 2027. nfvPPA has no approved US/EU treatments.

## SEC filing metadata
- accession: 0001437749-26-032502
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2026-10-13T12:36:31+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774926032502/0001437749-26-032502-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774926032502/crvo20261012_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-032502
- JSON: https://secwatch.observer/filing/0001437749-26-032502.json
- Plain text: https://secwatch.observer/filing/0001437749-26-032502.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.